ペプチド治療薬の世界市場及びパイプライン分析

◆英語タイトル:Global Peptide Therapeutics Market & Clinical Pipeline Insight 2016
◆商品コード:KUIK60804
◆発行会社(調査会社):KuicK Research
◆発行日:2016年3月
◆ページ数:1200
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single userUSD2,400 ⇒換算¥266,400見積依頼/購入/質問フォーム
Multi UserUSD4,800 ⇒換算¥532,800見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご確認ください。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はKuicK Research社の日本における正規販売代理店です。KuicK Research社の概要及び新刊レポートはこちらでご確認いただけます。
【レポートの概要】

Investigators are looking for different molecular entities that could be used for the development of viable therapeutics with commercial potential. Peptide therapeutics are one such category that has gained significant attention in past years. Several products have been launched in global market for different indications. Significant investments have been made by pharmaceutical companies in research and development (R&D) segment in order to come forth with innovative products. They also serve as building blocks for other therapeutics due to which it has become essential to study their nature in depth. In this way, it could be expected that peptide therapeutics for different ailments would be commercialized in global market in coming years.
Pharmacological profiles of peptide therapeutics is quite good due to which their numbers are increasing in global market. Inherently, peptide therapeutic offers various benefits like higher safety and efficacy levels along with higher tolerability. Metabolism of peptide therapeutics is quite predictable and it can be changed by investigators. In this way, higher control over pharmacological parameters could be observed. They can also be developed synthetically due to which variability could be made during their development. In this way, they are highly malleable and could be changes according to the requirements of drug development program. Their rate of development is high and low attrition rates related to peptide therapeutics have been also observed.

Pipeline of peptide therapeutics is quite strong due to which new products are expected to enter in global market in coming years. Several peptide therapeutics have already entered in various phases of clinical trials. Development of positive results will accelerate their market introduction in coming years. They are peptide in nature due to which chances of degradation is high, poor chemical stability and absorbance are some common caveats with their development. Immunogenicity is another factor that affect the efficacy of peptide therapeutics as some patients may develop severe side effects. Investigators have developed various procedure by which they are able to increase potency of peptide products. In this way, it could be observed that investigators are actively engaged in the development of peptide therapeutics.

Rapid discovery of peptide therapeutics is expected to increase the number of products in global market. Investigators are developing methods to identify new lead molecules that will serve as a basis for the development of new molecule. They are also being administrated in combination with other drugs to achieve higher therapeutic benefits. Alternate Route of Administration (RoA) is also being discovered for peptide drugs so as to maintain their efficacy. They are expected to have competition with small molecule drugs and development of new technologies which can hamper their marketing potential. Higher prices are other major factors that affect the commercialization potential of peptide therapeutics in global market. These factors have to consider by pharmaceutical companies while formulating marketing strategies.

Peptide therapeutics are versatile in nature due to which they can be used for the treatment of various disorders. Cancer, Central Nervous System (CNS), cardiovascular diseases, respiratory diseases and metabolic disorders are some the major segments where presence of peptide therapeutics could be observed. Besides this, different types of insulin has been developed by engineering peptide molecules. Their pharmacological efficacy is expected to be improved with time and new molecules are expected to enter in global market. Pharmaceutical companies have to come forth with new molecules in order to increase market shares of peptide therapeutics. Strong clinical pipeline indicates that the pharmaceutical firms are actively engaged in the development of peptide therapeutics. In this way, it could be expected that market size of global peptide therapeutics market will increase in coming years.

Peptide Segment Included In Report:

Cyclic-Peptide, Polypeptide, Glycopeptide, Oligopeptide, Depsipeptide, Neuropeptide, Dipeptides, Natriuretic Peptide, Lipopeptide, Opioid Peptide, Peptide Vaccine, Antimicrobial Cationic Peptide & Insulin

“Global Peptide Therapeutics Market & Clinical Pipeline Insight 2016” Report Highlights:

• Introduction to Peptides
• Mechanism of Action: Peptide Therapeutics, Peptide Vaccine & Peptide Hormone
• Global Peptide Therapeutics Market Dynamics
• Global Peptide Clinical Pipeline by Company, Indication & Phase
• Global Peptide Pipeline: 722 Peptides
• Majority Peptides in Preclinical Phase: 308 Peptides
• Commercially Available Peptides: 136 Peptides

【レポートの目次】

1. Introduction to Peptides

2. Mechanism of Action: Peptide Therapeutics, Peptide Vaccine & Peptide Hormone
2.1 Peptide Therapeutics
2.2 Peptide Vaccine
2.3 Peptide Hormone

3. Global Peptide Therapeutics Market Overview
3.1 Current Market Scenario
3.2 Global Peptide Pipeline Overview

4. Global Peptide Therapeutics Market Dynamics
4.1 Market Growth Drivers
4.1.1 Escalating Demand for Better Therapeutics
4.1.2 Research & Development
4.1.3 Advanced Peptide Synthesis Technology
4.1.4 Multiple Disease Indications
4.1.5 Strong Clinical Pipeline
4.2 Peptide Therapeutics Commercialization Challenges

5. Global Peptide Therapeutics Market Future Prospects

6. Cyclic Peptides Cinical Insight by Company, Indication & Phase
6.1 Preclinical till Preregistration

7. Dipeptides Cinical Insight by Company, Indication & Phase
7.1 Preclinical till Preregistration

8. Depsipeptides Cinical Insight by Company, Indication & Phase
8.1 Research till Phase-III

9. Glycopeptide Cinical Insight by Company, Indication & Phase
9.1 Preclinical till Phase-II

10. Insulin Cinical Insight by Company, Indication & Phase
10.1 Preclinical till Registered

11. Lipopeptides Cinical Insight by Company, Indication & Phase
11.1 Research till Phase-III

12. Natriuretic Peptide Cinical Insight by Company, Indication & Phase
12.1 Preclinical till Phase-III

13. Neuropeptide Cinical Insight by Company, Indication & Phase
13.1 Preclinical till Phase-II

14. Oligopeptides Cinical Insight by Company, Indication & Phase
14.1 Research till Preregistration

15. Opioid-Peptide Cinical Insight by Company, Indication & Phase
15.1 Preclinical till Preregistration

16. Peptides Cinical Insight by Company, Indication & Phase
16.1 Research till Registered

17. Multiple Peptides Cinical Insight by Company, Indication & Phase
17.1 Research till Preregistration

18. Marketed Peptides Cinical Insight by Company, Indication & Phase
18.1 Cyclic Peptides
18.2 Dipeptides
18.3 Depsipeptides
18.4 Glycopeptides
18.5 Insulins
18.6 Natriuretic-Peptides
18.7 Neuropeptides
18.8 Oligopeptides
18.9 Opioid-Peptides
18.10 Peptides
18.11 Multiple Peptides

19. Competitive Landscape
19.1 Amgen
19.2 Amylin Pharmaceuticals
19.3 Apitope Technology
19.4 BioPartners
19.5 BiondVax Pharmaceuticals Ltd
19.6 Boehringer Ingelheim
19.7 Circassia
19.8 Corden Pharma (Peptisyntha)
19.9 Eli Lily
19.10 Galena Biopharmaceuticals
19.11 GlaxoSmithKline
19.12 Hyperion Therapeutics
19.13 ImmunoCellular Therapeutics
19.14 Ipsen
19.15 Lonza
19.16 Merck
19.17 NovoNordisk
19.18 Par Pharmaceuticals
19.19 PeptiDream
19.20 Roche
19.21 Sanofi
19.22 Tarix Pharmaceuticals

Figure 1-1: Components of Peptide
Figure 1-2: Features of Peptide Therapeutics
Figure 2-1: Benefits of Peptide Modifications
Figure 2-2: Benefits of Computational Methods
Figure 2-3: Different Types of Peptide Formulation Vehicles
Figure 2-4: Mechanism of Vibativ
Figure 2-5: Mechanism of Liraglutide
Figure 2-6: Mechanism of Goserelin
Figure 2-7: Formulation of Orally Administrated Peptide Therapeutics
Figure 2-8: Mechanism of Peptide Vaccines
Figure 2-9: Mechanism of Live Vaccines
Figure 2-10: Mechanism of Toxoid & Inactivated Vaccine
Figure 2-11: Mode of Action of Peptide Cancer Vaccines
Figure 2-12: Mechanism of Peptide Hormones
Figure 2-13: Mechanism of Insulin
Figure 2-14: Mechanism of Genotropin
Figure 2-15: Mechanism of Pitressin
Figure 2-16: Mechanism of Glucagon
Figure 3-1: Global Peptide Market (US$ Billion), 2014-2020
Figure 3-2: Peptide Pipeline by Phase (%), 2016
Figure 3-3: Peptide Pipeline by Phase (Numbers), 2016
Figure 3-4: Cyclic Peptides Pipeline by Phase (%), 2016
Figure 3-5: Cyclic Peptides Pipeline by Phase (Numbers), 2016
Figure 3-6: Dipeptides Pipeline by Phase (%), 2016
Figure 3-7: Dipeptides Pipeline by Phase (Numbers), 2016
Figure 3-8: Depsipeptides Pipeline by Phase (%), 2016
Figure 3-9: Depsipeptides Pipeline by Phase (Numbers), 2016
Figure 3-10: Glycopeptides Pipeline by Phase (%), 2016
Figure 3-11: Glycopeptides Pipeline by Phase (Numbers), 2016
Figure 3-12: Insulin Pipeline by Phase (%), 2016
Figure 3-13: Insulin Pipeline by Phase (Numbers), 2016
Figure 3-14: Lipopeptides Pipeline by Phase (%), 2016
Figure 3-15: Lipopeptides Pipeline by Phase (Numbers), 2016
Figure 3-16: Natriuretic Peptides Pipeline by Phase (%), 2016
Figure 3-17: Natriuretic Peptides Pipeline by Phase (Numbers), 2016
Figure 3-18: Neuropeptides Pipeline by Phase (%), 2016
Figure 3-19: Neuropeptides Pipeline by Phase (Numbers), 2016
Figure 3-20: Oligopeptides Pipeline by Phase (%), 2016
Figure 3-21: Oligopeptides Pipeline by Phase (Numbers), 2016
Figure 3-22: Opioid-Peptides Pipeline by Phase (%), 2016
Figure 3-23: Opioid-Peptides Pipeline by Phase (Numbers), 2016
Figure 3-24: Multiple Peptides Pipeline by Phase (%), 2016
Figure 3-25: Multiple Peptides Pipeline by Phase (Numbers), 2016
Figure 4-1: Global Peptide Therapeutics Market Growth Drivers
Figure 4-2: Global Peptide Therapeutics Market Commercialization Challenges


【レポートのキーワード】

ペプチド治療薬

★調査レポート[ペプチド治療薬の世界市場及びパイプライン分析]販売に関する免責事項
★調査レポート[ペプチド治療薬の世界市場及びパイプライン分析]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆